ArticleAnnals of neurology2025
Predictive Value of Plasma Biomarkers in Tau-PET Transitions.
Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2026Trial
- Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Continuum of Core 1 biomarkers in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveThe objective of this study was to determine the predictive value of amyloid-positron emission tomography (PET) versus the plasma ratio of phosphorylated tau at threonine 217 (p-tau217) to non-phosphorylated tau217 (%p-tau217) for tau-PET transitions (T- to T+). The added value of combining plasma amyloid-β 42 and amyloid-β 40 (Aβ42/40) and %p-tau217 into an amyloid probability score (APS2) was also assessed.
methodsMayo Clinic Study of Aging (MCSA) participants had plasma markers measured at via mass spectrometry (MS), an amyloid-PET scan, and a tau-PET (meta-temporal region of interest [ROI]) negative scan (standardized uptake value ratio [SUVR] <1.29) at the index (baseline) date, along with one or more follow-up tau-PET scans. The BioFINDER-2 cohort was used for validation. Cox proportional hazards models adjusted for age, sex, and apolipoprotein (APOE) ε4 were used to assess predictors, with scaling to the interquartile range (IQR) for comparability of hazard ratios (HR).
resultsAmong 255 tau-PET negative MCSA participants (median age: 71.9 years), 37 converted to tau-PET positive (median follow-up time: 3.81 years). Higher %p-tau217 (HR: 1.52 [95% CI: 1.28-1.80]), amyloid-PET centiloid (HR: 1.47 [95% CI: 1.20-1.79]), and APS2 (HR: 1.62 [95% CI: 1.22-2.16]) predicted tau-PET conversion. However, Aβ42/40 (HR: 0.94 [95% CI: 0.54-1.66]) was not associated with tau-PET conversion. In the BioFINDER-2 cohort (605 tau-negative, median age: 70.2), 33 converted to tau-positive (median follow-up time: 2 years), with higher %p-tau217 (HR: 1.80 [95% CI: 1.50-2.17]), amyloid-PET centiloid (HR: 2.29 [95% CI: 1.77-2.97]), and lower Aβ42/40 (HR: 2.38 [95% CI: 1.17-4.83]) predicting conversion.
interpretationIn two cohorts, %p-tau217 was associated with tau-PET conversion, comparable to amyloid-PET. APS2 also predicted conversion in the MCSA cohort, whereas Aβ42/40 predicted conversion in the BioFINDER-2 cohort, which had more individuals with cognitive impairment. ANN NEUROL 2025;98:1249-1260.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.